Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head ... this novel IO combination in head and neck squamous cell cancers with PD-L1 CPS <1.
A recent study published in the journal Scientific Reports correlates higher levels of pollutant particulate matter to higher occurrences of head and neck aerodigestive cancer. The article ...